



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 



## Interleukin-29, human recombinant (rHuIL-29)

**Catalog No:** 08552  
**Lot No:** XXXXX  
**Source:** *E. coli*  
**Synonyms:** Interleukin-29, IL-29, IFN-Lambda 1, Interferon-Lambda 1, Cytokine ZCYTO21, IL29, IFNL1, ZCYTO21

### Background

IL-29 is distantly related to type I interferons and the IL-10 family. Expression of IL-29 is induced by viral infection which interacts with a heterodimeric class II cytokine receptor that consists of interleukin 10 receptor, beta (IL10RB) and interleukin 28 receptor, alpha. IL-29 exhibits common features with type I IFNs such as antiviral activity, antiproliferative activity and in vivo antitumour activity. IL-29 acts similarly to IFNs, but is less effective generally and has activity in a more limited range of cell lines. IFN-ambda 1, IFN-lambda 2 and IFN-lambda3 are closely positioned genes on human chromosome 19. IL-29 induces ELR(-) CXC chemokine mRNA in human peripheral blood mononuclear cells, in an IFN-gamma-independent manner. IL-29 is able to generate tolerogenic DCs, an activity that could thwart IFN-beta functions. IL-29 produced in response to viral infection, activates both monocytes and macrophages producing a restricted panel of cytokines and therefore is an important factor in activating innate immune responses at the site of viral infection. IFN-Lambda 1 antiviral and antiproliferative activity requires Interferon-Lambda 2 receptor tyrosine residues.

### Description

Interleukin-29 human recombinant produced in *E. coli* is a single, non-glycosylated, polypeptide chain containing 181 amino acids and having a molecular mass of 20 kDa.

### Physical Appearance

Sterile filtered white lyophilized (freeze-dried) powder.

### Formulation

Lyophilized from a 0.2 µm filtered solution containing no additives.

### Solubility

It is recommended to reconstitute the lyophilized Interleukin-29 in sterile 18 MΩ-cm H<sub>2</sub>O not less than 100 µg/ml, which can then be further diluted to other aqueous solutions.

### Stability

Lyophilized IFN-Lambda 1, although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution IFN-Lambda 1 Recombinant should be stored at 4°C between 2-7 days and for future use below -18°C. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA). Please prevent freeze-thaw cycles.

### Purity

Greater than 90% as determined by (a) Analysis by RP-HPLC, (b) Analysis by SDS-PAGE.

### Amino Acid Sequence

GPVPTSKPTTT GKGCHIGRFK SLSPQELASF KKARDALEES LKLKNWSCSS PVFPGNWDLR LLQVRERPVA LEAELALTLK  
VLEAAAGPALE DVLDQPLHTL HHILSQLQAC IQPQPTAGPR PRGRLHHWLH RLQEAPKKES AGCLEASVTF NLFRLLRDLK  
YVADGNLCLRT STHPEST



**Usage**

This product is offered by Biomol for research purposes only. Not for diagnostic purposes or human use. It may not be resold or used to manufacture commercial products without written approval of Biomol GmbH.